Key facts
- Notable investors include Miracleplus, Innoangel Fund, CDH Investments, CITIC Capital, Aeon Holdings — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Jinhe Biology
- ·The full record, as it builds
Funding rounds
No funding rounds for Jinhe Biology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jinhe Biology
Developer of cell-free synthesis technology intended to promote the development of the industry. The company is committed to maximising the productivity of biological enzymes and creating a molecular material manufacturing platform, enabling clients to have advanced cell-free synthesis technology in the field of synthetic biology.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2022
- Employees
- 65
- Website
- oxsyns.com/
- Ownership
- Privately Held (backing)
Jinhe Biology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jinhe Biology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jinhe Biology in its N-PORT filings yet. We sweep new filings monthly.